News

A kidney relief  drug worth €673m
Enlarge image

BusinessSwedenUK

A kidney relief drug worth €673m

10.10.2012 - British-Swedish Astra Zeneca pays Californian start-up Ardelyx up to €673m to get hold on exclusive rights for their NHE3 inhibitor programme.

After a setback this summer with an anti-obesity drug, Astra Zeneca is trying to pick up pace by getting hold on a new class of drugs. The small molecules developed by Ardelyx from Fremont (USA) target a sodium transporter on the surface of the intestinal epithelia. Astra Zeneca sees promising options for the treatment of diseases ranging from cardiovascular defects to diabetes or chronic kidney problems. On 8 October, the two companies announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme worth up to €673m. The lead compound – Phase 2-ready RDX5791 – showed activity against constipation-predominant irritable bowel syndrome (IBS-C) and is also clinically tested in end-stage renal disease (ESRD) and chronic kidney disease (CKD). Under the terms of the agreement, Astra Zeneca will pay €27m up-front. Development milestones could rinse another €184m into Ardelyx’ pockets. With launch and commercialisation milestones and tiered double-digit royalties, the whole deal could yield up to €673m. Ardelyx will fund Phase II trials and Astra Zeneca further clinical development.

Aside from RDX5791, several other compounds all targeting the main transporter of sodium in the intestines, NHE3, are also subject to the deal. The effect of RDX5791 can be compared with living on a low-salt diet. Preventing the uptake of sodium ions into the body unburdens failing kidneys to eliminate excess sodium. Blocked sodium will be excreted with the faeces instead. A positive systemic effect is that no sodium will accumulate in intravascular and interstitial tissues, so hypertension and oedema formation could be effectively averted. Beyond NHE3 inhibitors, Ardelyx has three separate non-systemic preclinical compounds that are all not covered by the Astra Zeneca deal. Although targeting different molecules in the gut, they share a common property in that they are not absorbed by the gastrointestinal epithelia and are passed through the gastrointestinal tract without being altered.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/a-kidney-relief-drug-worth-eur673m.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.07 CHF16.67%
  • EUROFINS SCIENTIFIC (F)283.68 EUR11.25%
  • MEDIGENE (D)9.35 EUR10.65%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.00%
  • NORDIC NANOVECTOR (N)24.40 NOK-9.29%
  • EVOTEC (D)3.33 EUR-6.20%

TOP

  • DBV Technologies (F)55.76 EUR31.0%
  • VERONA PHARMA (UK)5.20 GBP24.7%
  • MEDIGENE (D)9.35 EUR20.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)24.40 NOK-30.5%
  • TRANSGENE (F)3.75 EUR-24.2%

TOP

  • ADOCIA (F)69.25 EUR398.9%
  • 4SC (D)4.88 EUR369.2%
  • WILEX (D)3.54 EUR321.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.20 SEK-68.1%
  • NEOVACS (F)1.13 EUR-66.9%

No liability assumed, Date: 01.07.2015